Women’s health / Success case
Commercial and financial due diligence on a $45M femtech investment, delivered in 7 days
Market, competition, pricing, a financial sanity check and a valuation range for a clinical-stage women’s health biotech.
At a glance
Investment reviewed
$45M
An independent view before the fund committed.
- The askIs this real?
- Seven daysMarket, rivals, pricing, value
- The callDon’t invest at these terms
- The fund passed$45M kept
Delivered in
Seven days
Against the usual six weeks
Recommendation
Pass
The fund followed it
Client
European private equity group, ~€2B under management
- Private equity
- Women’s health
Scope
- Commercial due diligence
- Competitive landscape
- Pricing comparables
- Valuation range
The challenge: a biotech deal, outside the fund’s lane
Out of lane. The fund does buyouts and growth deals. A pre-revenue biotech two years from launch is valued on trial data and comparables its team couldn’t read.
The timing. The opportunity was live, and the deal team needed an answer in days, not the six weeks a confirmatory review normally takes.
The management case. The pitch claimed no competing therapies and projected margins that looked too good. Both needed testing before anyone wrote a cheque.
The question: three things, in order
Each answered in language a generalist investment committee could act on.
Is the market real?
And is the company positioned in it, or only near it?
Who is the competition, really?
Beyond the names in the management presentation, across every target condition.
What is it worth?
At what valuation $45M makes sense, given where comparable companies have traded.
What we found: a real market, and a credible position
The market is real and under-served.
- 15% of reproductive-age couples are affected by infertility
- 186M people worldwide
- 4% of global medical research spend goes to women’s health
- ~6x growth in fertility-focused VC funding over the previous decade
The position is credible too: the company is one of the first to target the microbiome for infertility, while most rivals pursue hormonal therapy.
What we found: the pitch against the evidence
No competitors, software-grade margins, and a valuation the company’s own forecast was meant to justify.
Three claims carried the investment thesis. The fund had no in-house biotech expertise to test them, and the management presentation was the only source in the room.
None of the three claims survived a week of independent work.
We named the closest competitor the deck said didn’t exist, found margin projections roughly double the sector, and anchored the valuation on stage comparables. Recommendation: don’t invest at the proposed terms.
The numbers, against the benchmarks
The management case next to what comparable companies actually deliver and are worth.
| Measure | The company | Comparables |
|---|---|---|
| Gross margin, from year four | 88%+ | 40-75% |
| EBITDA margin, from year four | 60%+ | 28-35% |
| Price per treatment | $5,500-12,000 | $3,500-25,000 |
| Valuation anchor, Phase I-III | Its own forecast | Stage comparables: $7-13M early, $26-30M+ late |
The pricing held up and supports the volume case. The margins and the valuation didn’t: with launch two years out, there was no multiple to apply, only stage comparables, and a competitive field that wasn’t thin.
What we learned: why PE funds get biotech wrong
Four traps a generalist fund walks into, and this deal had all four.
The deck is the only source
Independently sourced references are worth ten times a management list. The competitor claim here is the textbook case.
The model looks like software
Biotech margins in a pitch routinely beat anything the sector delivers, and nobody has a benchmark on the page.
Pre-revenue has no multiple
A company two years from launch can only be valued on stage comparables, which a generalist doesn’t have.
Nobody has six weeks
Competitive deals get decided before a full review ends. Expedited specialist work runs within two weeks; this ran in seven days.
What investors are rewarding in femtech now
Proof over potential: adoption, regulatory progress and partnerships, not product promise alone.
- $392M across 44 femtech deals, 1 January to 21 September 2026
- +70% in capital, while deal count fell 15%: fewer, bigger bets
- -13% in funding once rounds above $50M are excluded
- 35% → 16% fertility care’s share of deals, a sharp decline
Strategic healthcare investors are in a growing share of rounds where clinical access and distribution matter.
What we delivered, in seven days
A pack the investment committee could read without a scientist, and a clear call.
A 30-page due diligence pack
Market, positioning, competition, pricing, the financial outlook, comparables, precedents and a written conclusion.
The competitive landscape
IVF, endometriosis and preterm birth: incumbents, new entrants, big pharma and academic programmes.
Comparables and a valuation
Three comparable sets, public and private, and a valuation range with the risks named in plain language.
Results
- Pass the recommendation, and the fund followed it
- $45M kept in the fund
- 3 findings that made the call: a named competitor, margins about double the sector, and a stage-based valuation anchor
Weighing a deal outside your sector?
We run independent due diligence for investors: market, competition and valuation, usually in 2–6 weeks.

















